申请人:——
公开号:US20020161237A1
公开(公告)日:2002-10-31
Compounds of formula 1 and 1-1,
1
wherein R
1
is hydrogen, hydroxy, amino or halogen, R
2
is hydrogen, hydroxy, or halogen and R
3
is hydrogen (Formula 1) or R
1
is hydrogen and R
2
and R
3
taken together with the ethenylene group connecting them form phenyl, pyrrole, pyrroline, oxopyrroline, pyrazole, triazole, or imidazole (Formula 1-1), A is
2
R
4
R
5
are hydrogen, methyl, ethyl or halogen except that R
4
r
5
cannot both be hydrogen; and
1) B is hydrogen, or lower alkyl; or
2) B is
3
where R
6
R
7
R
8
and R
9
are independently hydrogen, hydroxy, aminosulfonyl, halogen, lower alkoxy, cyano, amino, lower alkyl, lower alkyl amino, or nitro;
or 3) B is
4
where R
10
is hydrogen, hydroxy, halogen, or lower alkyl and C is a five- or six- membered ring with 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur, which ring may be unsubstituted or mono- or di- substituted with lower alkyl, cycloalkyl, amino, or substituted amino;
4) B is
5
where X and Y are independently methylene or nitrogen; or
5) B is
6
where at leat one of T, U, V, or W is nitrogen, and any of T, U, V or W which is carbon may be substituted with lower alkyl, lower alkyl amino, lower alkoxy, hydroxy, aminosulfonyl, halogen, cyano, amino, or nitro; or
6) B is
7
where Y is carbon or nitrogen;
or
7) B is a five-membered aromatic ring with 1 to 3 heteratoms selected from nitrogen, oxygen, and sulfur which ring may be unsubstituted or mono- or di-substituted with lower alkyl, cycloalky, trifluoroloweralkyl, amino, halogen, substituted amino, or which ring may be fused with a 5 or 6 membered aromatic ring containing 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur; and pharmaceutically acceptable salts thereof, and related prodrugs, pharmaceutical compositions and methods of treatment, which compounds are useful for treating psoriasis.
化合物的公式为1和1-1,其中R1是氢,羟基,
氨基或卤素,R2是氢,羟基或卤素,R3是氢(公式1)或R1是氢,R2和R3与它们连接的
乙烯基共同形成苯,
吡咯,
吡咯烷,氧代
吡咯烷,
吡唑,三唑或
咪唑(公式1-1),A是2R4R5是氢,甲基,乙基或卤素,但R4R5不能都是氢; 1)B是氢或低烷基; 或2)B是3,其中R6R7R8和R9独立地是氢,羟基,
氨基磺酰基,卤素,低烷氧基,
氰基,
氨基,低烷基,低烷基
氨基或硝基; 或3)B是4,其中R10是氢,羟基,卤素或低烷基,C是具有0到3个异原子的五元或六元环,所述异原子从氮,氧和
硫中选择,所述环可以是未取代的或单取代的或二取代的,所述取代基为低烷基,环烷基,
氨基或取代
氨基; 4)B是5,其中X和Y独立地是亚甲基或氮; 或5)B是6,其中至少有一个T,U,V或W是氮,任何为碳的T,U,V或W可以用低烷基,低烷基
氨基,低烷氧基,羟基,
氨基磺酰基,卤素,
氰基,
氨基或硝基取代; 或6)B是7,其中Y是碳或氮; 或7)B是具有1到3个异原子的五元芳香环,所述异原子从氮,氧和
硫中选择,所述环可以是未取代的或单取代的或二取代的,所述取代基为低烷基,环烷基,三
氟低烷基,
氨基,卤素,取代
氨基,或者所述环可以与包含0到3个异原子的五元或六元芳香环融合; 以及其药学上可接受的盐,相关的前药,制药组合物和治疗方法,这些化合物对于治疗
银屑病是有用的。